Unified Patent Court (UPC) analytics are now available. Check here

EP2887961

NOVARTIS
Application Number
EP13750725A
Filing Date
Aug 22, 2013
Status
Revoked
Dec 9, 2022
Grant Date
Apr 28, 2021
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Biblio Summary

The patent EP2887961B1 was granted on Apr 28, 2021 by Novartis The patent is currently Revoked.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ALGEMEEN OCTROOI EN MERKENBUREAUJan 28, 2022ADMISSIBLE
GENERICS UKJan 28, 2022ADMISSIBLE
STADA ARZNEIMITTELJan 28, 2022ADMISSIBLE
TEVA PHARMACEUTICAL INDUSTRIESJan 27, 2022ADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBJan 27, 2022ADMISSIBLE
ALFRED E TIEFENBACHERJan 26, 2022ADMISSIBLE

Patent citations in opposition refer to prior patents or publications that may challenge the validity of a contested patent. These references help assess whether the invention is truly novel or overlaps with existing intellectual property.

Citation PhasePatent NumberPatent LinkCited Text
OppositionWO2007056546
N/A
OppositionUS5217996
N/A
OppositionWO2009061713
N/A
OppositionWO03059345
N/A
OppositionWO2012027237
N/A
OppositionWO2014029848
N/A
OppositionWO2006086456
N/A

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.